West Pharmaceutical (WST) stock plummeted 24.11% on Thursday morning's pre-market session, following the company's weaker-than-expected guidance for 2025 due to factors like biotech customers reducing pandemic-era inventories and headwinds from a strong U.S. dollar.
The medical equipment maker forecast 2025 adjusted earnings per share of $6 to $6.20, well below analysts' average estimate of $7.44. It also projected full-year revenue between $2.88 billion and $2.91 billion, missing expectations of $3.04 billion.
West Pharma cited the ongoing impact of destocking by its biotech clients, who had built up inventories during pandemic supply chain disruptions. The company's CEO Eric Green noted that "the impact of destocking continues to moderate" but remains a challenge. A strong U.S. dollar also weighed on the outlook by impacting overseas revenues.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.